Fitch Affirms Rating for Thermo Fisher Scientific | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Fitch Rating today affirmed its "A-" issuer default rating for Thermo Fisher Scientific, following the firm's announcement that it plans to acquire allergy and autoimmune diagnostics firm Phadia for €2.47 billion ($3.5 billion).

The ratings apply to $4.3 billion of debt outstanding as of April 2. The ratings outlook on Thermo Fisher is "Stable," Fitch said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.